Its ability to constitutively activate the JAK-STAT pathway has made it a rational therapeutic target, with JAK inhibitors such as ruxolitinib having been successfully used to treat neoplasms driven by this alteration [11,14,15]. This evidence concerns the gene SOAT1 and neoplasm.